Suboxone induction process: what to expect at your first clinic visit

If you or a loved one are preparing for a Suboxone induction, it helps to know the clinical steps, timing checkpoints, and safety checks clinicians use. This article explains the usual outpatient pathway in clear stages: pre-induction assessment, how and when clinicians start buprenorphine/naloxone, supervised Day 1 titration, early follow-up, common risks including precipitated withdrawal, alternative induction options, and how to access same-day intake in Ontario.

Pre-induction assessment: what clinicians review before you start

Medical history and current medications

Before induction a clinician will review your medical history, current prescriptions, and substances used recently. This includes benzodiazepines, alcohol, and prescription opioids because concurrent sedatives increase the risk of respiratory depression and must shape monitoring plans. Your clinician will check for liver disease, other medical conditions, and any prior reactions to opioid treatment.

Last opioid use and timing

Clinicians need the exact time of your last opioid use because induction timing depends on the opioid type and how long it has been since use. For short-acting opioids, guidance is to wait until objective signs of withdrawal are present before administering buprenorphine/naloxone to reduce the risk of precipitated withdrawal. See the Suboxone product information for timing details (DailyMed).

Baseline checks and screening tests

Expect basic vital signs, a targeted symptom assessment using a withdrawal scale, and possibly urine toxicology. Pregnancy screening and a medication reconciliation are routine for safety. This information determines whether an in-clinic supervised induction is appropriate or whether an alternative pathway is safer. Clinicians will also discuss transport plans after the visit because lightheadedness or drowsiness can occur initially.

When to start Suboxone: timing and objective withdrawal signs

What clinicians mean by objective signs of moderate withdrawal

Objective signs include sweating, yawning, pupil changes, tremor, piloerection, restlessness, an elevated heart rate, and gastrointestinal upset. Clinicians look for several signs together and may use a formal rating scale, such as the Clinical Opiate Withdrawal Scale, during assessment to confirm moderate withdrawal before starting buprenorphine.

Minimum time since last opioid use

For people dependent on short-acting opioids, an induction dose should only be given when objective moderate withdrawal appears, and not less than six hours after last use in typical scenarios. Timing differs for long-acting opioids or methadone, so clinicians use a different plan in those cases. Provincial induction handouts describe a cautious stepwise approach for initial dosing (BC guidelines).

Day 1 supervised induction and titration: what happens in clinic

First administration and route

Suboxone film is given sublingually during induction and must be placed under the tongue to dissolve. For induction, the film route is recommended; once induction is complete, patients can be switched between sublingual and buccal routes with monitoring as needed. Health Canada advises careful monitoring when switching dosage forms (Health Canada).

Incremental dosing and observation

Clinicians typically start with a low induction dose and may give incrementally higher doses while observing the patient over several hours. Provincial guidance supports supervised titration where small doses are given at roughly two hour intervals until withdrawal is controlled for Day 1. Clinician judgement guides the exact dose and pace, and no single fixed schedule fits every patient (BC guidelines).

What you will feel during titration

Many people feel relief of withdrawal symptoms as buprenorphine begins to act. Initial side effects such as lightheadedness, sweating, or nausea sometimes occur and usually pass. If symptoms worsen sharply after the first dose, the team will assess for precipitated withdrawal and provide supportive care. Clinicians monitor breathing, heart rate, and symptom scores while you are observed.

Managing the main risks: precipitated withdrawal and formulation switching

What precipitated withdrawal is and why it happens

Precipitated withdrawal occurs when buprenorphine, a partial opioid agonist with high receptor affinity, displaces full opioid agonists from receptors, causing a rapid increase in withdrawal symptoms. This is why starting buprenorphine only after objective withdrawal is critical (DailyMed).

How clinicians recognise and respond

If precipitated withdrawal occurs, clinicians provide symptomatic treatment such as anti-nausea medication, fluids if needed, and close monitoring. They may delay further dosing and arrange short-term observation. In outpatient settings the team will communicate a plan for rapid follow-up and may refer for higher-acuity care if symptoms remain severe.

Switching between routes or formulations

Changing from one dosage form to another alters drug exposure. Health Canada highlights the need to monitor patients when switching between sublingual and buccal forms to avoid underdosing or overdosing early after induction (Health Canada). Your clinician will explain any planned change and check symptoms closely after the switch.

Special pathways: inductions after methadone or with micro-dosing or unwitnessed methods

Induction for people on methadone or other long-acting opioids

When dependence is on long-acting opioids such as methadone, clinicians commonly use a modified strategy rather than starting standard Suboxone immediately. Options include tapering methadone first, a short course of buprenorphine monotherapy before combined formulations, or a longer monitored induction tailored to the patient. These plans reduce the chance of precipitated withdrawal and require clinician expertise.

Micro-dosing and unwitnessed induction

Micro-dosing introduces very small amounts of buprenorphine while continuing other opioids to reduce the chance of precipitated withdrawal. Unwitnessed induction is an option when supervised attendance is not possible. Both approaches follow published recommendations and require careful planning and follow-up. See micro-dosing guidance for procedural details (CPSM Manitoba).

When specialist referral is advised

Complex cases such as pregnancy, unstable psychiatric illness, heavy benzodiazepine use, or high-dose methadone should prompt discussion with addiction specialists or referral to services with experience in alternative induction pathways. Specialist teams can provide tailored monitoring and hospital-based induction if needed.

Early follow-up and first week monitoring: what your clinic will check

Timing of early checks

Clinics usually schedule a follow-up within 24 to 48 hours after the initial induction to confirm withdrawal control and to adjust dose if needed. Additional early visits over the first week help clinicians stabilise the dose and check for adverse effects. Dose stabilisation commonly takes several days to a few weeks depending on response.

Safety checks during follow-up

Follow-up may include withdrawal symptom assessment, vital signs, medication reconciliation, and urine screening if part of local practice. The care team will also check interactions with other medications, counsel on safe storage, and discuss signs that require urgent review such as breathing difficulty or severe confusion.

How to access same-day outpatient induction in Ontario and what to bring

What to expect at a clinic like Road To Recovery

Road To Recovery operates outpatient clinics across Ontario offering medication options including Suboxone and provides same-day intake models where new OAT patients are triaged by a nurse and seen by a physician on the same day they start, reducing delays in care. Clinics coordinate mental health referrals when needed and offer a confidential, judgement-free environment (Road To Recovery).

What to bring to your appointment

Bring the following to streamline assessment and improve safety:

• Photo identification
• A current list of prescribed medications and over-the-counter substances
• The exact time of your last opioid use
• Contact information for a support person if you want them involved
• Any relevant health cards or prior clinic notes if available

Confidentiality and referrals

Clinics maintain confidential, judgment-free care and can coordinate psychiatry referrals locally or virtually through partners such as CAMH and OTN when mental health support is needed as part of Opioid Agonist Therapy. If you are switching from a monthly injection or another formulation, read more about the process in our article on Sublocade to Suboxone: What to Expect During the Switch (2026).

Choosing the right induction pathway: decision criteria clinicians use

Key clinical factors

Clinicians weigh several criteria when selecting an induction method: the opioid type and half-life, severity of dependence and withdrawal, concurrent sedative use, pregnancy, and access to supervised services. A clear, accurate history and the checklist above help the team decide quickly and safely.

Quick checklist to bring to your appointment

• Type of opioid(s) used and time of last dose
• Daily opioid amount or usual frequency
• List of other substances and prescribed sedatives
• Any history of severe withdrawal or hospitalisations
• Pregnancy status if applicable

Frequently asked questions

When should I start Suboxone after my last opioid use?

For short-acting opioids clinicians generally wait until objective signs of moderate withdrawal appear and not less than six hours after last use. The exact timing depends on opioid type and clinical judgement, so discuss your last use with the clinician at intake (DailyMed).

What is precipitated withdrawal and how will the clinic manage it?

Precipitated withdrawal is a rapid worsening of withdrawal after buprenorphine displaces full agonists. Clinics monitor for it during induction, provide supportive care, pause further dosing if needed, and may arrange closer follow-up or symptomatic treatments until symptoms resolve (DailyMed).

Can I get a same-day Suboxone induction at Road To Recovery in Ontario?

Yes. Road To Recovery offers same-day intake for new OAT patients where a nurse triages and a physician assesses patients on the same day to begin treatment, subject to clinical eligibility and a completed intake assessment (Road To Recovery).

How is induction different if I am on methadone or received a Sublocade injection?

Long-acting opioids such as methadone or recent extended-release injections require a tailored induction strategy. Clinicians may use buprenorphine monotherapy, adjusted timelines, or specialist referral. If you are transitioning from Sublocade, read the clinic’s guidance on switching to Suboxone (Road To Recovery).

What should I bring to my first Suboxone induction appointment?

Bring photo ID, a medication list, time of last opioid use, contact for a support person, and any prior treatment notes. Providing accurate information helps the team choose the safest induction pathway for you.

For reliable references used in this article see the Suboxone product monograph and provincial induction materials such as the DailyMed product information, Health Canada safety communications, the BC induction handout, and micro-dosing guidance from provincial colleges.

Road To Recovery can help you begin the Suboxone induction process with same-day intake and coordinated mental health referrals. Visit our site to start the secure intake process or to find a clinic near you.